Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Neoplasms 1Neoplasm Metastasis 1KRAS p.G12C Mutant Advanced Solid Tumors 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 2Pemetrexed 2Docetaxel 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trametinib 1spartalizumab 1sotorasib 1sintilimab 1palbociclib 1netrin-1 inhibitor NP137 1atezolizumab 1Panitumumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Injections 1Fluorouracil 1Everolimus 1Drug Therapy 1Cetuximab 1Afatinib 1ASP1570 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Solid Tumors × sotorasib × Clear all
NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡